The genomic classifier separates patients into a gLoR or gHiR group based on the presence (+) or absence (−) of Notch1/FBXW7 (N/F) and Ras/PTEN (R/P) mutations. Subsequent integration with MRD status and WBC count allows stratification into 3 discrete clinical risk groups. Interm, intermediate. Adapted from Figure 5 in the article by Petit et al on page 289.